AN OBSERVATIONAL STUDY TO VALIDATE THE SYMPTOMATOLOGY AND TO EVOLVE THE DIAGNOSTIC METHODOLOGY OF SIRAKKAMBA VATHAM THROUGH SIDDHA DIAGNOSTIC TOOLS

Sirakamba vatham is a clinical entity described by Sage Yugi in his treatise Yugi Vaithiya Chinthamani- 800, as one among the 80 types of Vatha diseases described in Siddha system of medicine. The study was aimed at in depth analysis of the clinical features mentioned under Sirakamba vatham of Siddha literature and to evolve standard Siddha diagnostic methods for management for Sirakamba vatham. This study was an observational, single center study with the sample size of 26, divided into Group I (control group) having normal individuals and group II (cases with Sirakkamba vatham). At the end of the study, it was concluded, that the symptoms of Sirakkamba vatham closely resembled the symptoms of Cerebro Vascular Accident especially of posterior circulation stroke

VALIDATION OF SIDDHA PATHOLOGICAL CONCEPTS OF SIRAKAMBAVATHAM AND ITS PARALLEL ANALYSIS WITH CEREBRO VASCULAR ACCIDENTS (STROKE)

The Siddha system of medicine is widely practiced in South India and consists of an enormous classical literature that emphasize on pathological basis of disease. Contrary to conventional pathological basis of diseases, the Siddha pathology is solely based on the humoral makeup of individuals and rests on the conceptual framework formed by 96 Thathuvams (philosophies). These concepts connect the physical and inert energies of human body facilitating its existence at subtle and gross levels. Sirakkambavatham is one among the 80 Vatha diseases mentioned in the Siddha literature Yugivaithiyasinthaamani. The present literature survey has been conducted to provide an updated integrative framework of information about the pathological concepts of Sirakkambavatham from Siddha literature and its parallel analysis with Cerebrovascular accidents (Stroke).Validating the traditional text in the limelight of modern literature unveils the traditional wisdom of ancient saints of South India and provides a better approach for disease diagnosis, prevention and its management

Fetomaternal outcomes in pregnancy complicated by epilepsy: a retrospective study

Background: This study is conducted to find out possible course and complications of epilepsy and its treatment in mother and fetus as many women will be anxious regarding this high-risk condition.Methods: This is a retrospective study conducted in department of obstetrics and gynaecology, AIMS Kochi from 2012-2019. Out of a total of 7045 deliveries during that period, we identified 64 patients with epilepsy complicating pregnancy. Antepartum, intrapartum and postpartum details of 57 patients whose data was available in electronic medical records was collected and analysed using SPSS 17 software.Results: In this study we noted that the incidence of epilepsy was 0.009%. the 50% of patients were in 25-30 years age group. More than 98% were on long term antiepileptic drugs. Majority were on monotherapy, most commonly on leviteracetam and were well controlled with monotherapy. The 38.5% had recurrence of seizures during pregnancy, mostly in latter half of pregnancy. Patients with seizure free interval of 9 months prior to pregnancy did not have any further epilepsy episodes. The incidence of other medical and obstetric complications was found to be similar to general population. There was 10% incidence of IUGR and fetal anomaly.Conclusions: The seizures were well controlled with monotherapy and we found that generally pregnancy and delivery is well tolerated and overall neonatal outcomes were good

Prediction of Indoor Air Quality in a School Building Using Risk Model

Source: ICHE Conference Archive - https://mdi-de.baw.de/icheArchiv

End-functionalized glycopolymers as mimetics of chondroitin sulfate proteoglycans

Glycosaminoglycans are sulfated polysaccharides that play important roles in fundamental biological processes, such as cell division, viral invasion, cancer and neuroregeneration. The multivalent presentation of multiple glycosaminoglycan chains on proteoglycan scaffolds may profoundly influence their interactions with proteins and subsequent biological activity. However, the importance of this multivalent architecture remains largely unexplored, and few synthetic mimics exist for probing and manipulating glycosaminoglycan activity. Here, we describe a new class of end-functionalized ring-opening metathesis polymerization (ROMP) polymers that mimic the native-like, multivalent architecture found on chondroitin sulfate (CS) proteoglycans. We demonstrate that these glycopolymers can be readily integrated with microarray and surface plasmon resonance technology platforms, where they retain the ability to interact selectively with proteins. ROMP-based glycopolymers are part of a growing arsenal of chemical tools for probing the functions of glycosaminoglycans and for studying their interactions with proteins

Translating tumor biology into personalized treatment planning: analytical performance characteristics of the Oncotype DX® Colon Cancer Assay

<p>Abstract</p> <p>Background</p> <p>The Onco<it>type </it>DX^®Colon Cancer Assay is a new diagnostic test for determining the likelihood of recurrence in stage II colon cancer patients after surgical resection using fixed paraffin embedded (FPE) primary colon tumor tissue. Like the Onco<it>type </it>DX Breast Cancer Assay, this is a high complexity, multi-analyte, reverse transcription (RT) polymerase chain reaction (PCR) assay that measures the expression levels of specific cancer-related genes. By capturing the biology underlying each patient's tumor, the Onco<it>type </it>DX Colon Cancer Assay provides a Recurrence Score (RS) that reflects an individualized risk of disease recurrence. Here we describe its analytical performance using pre-determined performance criteria, which is a critical component of molecular diagnostic test validation.</p> <p>Results</p> <p>All analytical measurements met pre-specified performance criteria. PCR amplification efficiency for all 12 assays was high, ranging from 96% to 107%, while linearity was demonstrated over an 11 log₂concentration range for all assays. Based on estimated components of variance for FPE RNA pools, analytical reproducibility and precision demonstrated low SDs for individual genes (0.16 to 0.32 C_Ts), gene groups (≤0.05 normalized/aggregate C_Ts) and RS (≤1.38 RS units).</p> <p>Conclusions</p> <p>Analytical performance characteristics shown here for both individual genes and gene groups in the Onco<it>type </it>DX Colon Cancer Assay demonstrate consistent translation of specific biology of individual tumors into clinically useful diagnostic information. The results of these studies illustrate how the analytical capability of the Onco<it>type </it>DX Colon Cancer Assay has enabled clinical validation of a test to determine individualized recurrence risk after colon cancer surgery.</p

Web Application Shielding

In the olden days computer networks were used for sending emails so there was no issue of security but now a days people who are using internet as sharing tool are hacking the financial products like credit cards, debit cards by hacking the pin numbers and passwords and are misusing the accounts. There are several threats for the online applications such as hacking, intrusion and so on. Nowadays, application security is rapidly being recognized as a top priority. The systems store and retrieve knowledge and it'll shield the information from unauthorized users, disclosure, modification or destruction. Systems can make sure that the users have the authority to access the information, load new knowledge, or update existing knowledge. It is a very huge and complex task to provide security for a web application. So to avoid such problems a Web Application Shielding with the help of encryption techniques can be developed. This prevents hackers from exploiting vulnerabilities. This provides a higher level of security

Biomarker discovery for colon cancer using a 761 gene RT-PCR assay

<p>Abstract</p> <p>Background</p> <p>Reverse transcription PCR (RT-PCR) is widely recognized to be the gold standard method for quantifying gene expression. Studies using RT-PCR technology as a discovery tool have historically been limited to relatively small gene sets compared to other gene expression platforms such as microarrays. We have recently shown that TaqMan^®RT-PCR can be scaled up to profile expression for 192 genes in fixed paraffin-embedded (FPE) clinical study tumor specimens. This technology has also been used to develop and commercialize a widely used clinical test for breast cancer prognosis and prediction, the Onco <it>type</it>DX™ assay. A similar need exists in colon cancer for a test that provides information on the likelihood of disease recurrence in colon cancer (prognosis) and the likelihood of tumor response to standard chemotherapy regimens (prediction). We have now scaled our RT-PCR assay to efficiently screen 761 biomarkers across hundreds of patient samples and applied this process to biomarker discovery in colon cancer. This screening strategy remains attractive due to the inherent advantages of maintaining platform consistency from discovery through clinical application.</p> <p>Results</p> <p>RNA was extracted from formalin fixed paraffin embedded (FPE) tissue, as old as 28 years, from 354 patients enrolled in NSABP C-01 and C-02 colon cancer studies. Multiplexed reverse transcription reactions were performed using a gene specific primer pool containing 761 unique primers. PCR was performed as independent TaqMan^®reactions for each candidate gene. Hierarchal clustering demonstrates that genes expected to co-express form obvious, distinct and in certain cases very tightly correlated clusters, validating the reliability of this technical approach to biomarker discovery.</p> <p>Conclusion</p> <p>We have developed a high throughput, quantitatively precise multi-analyte gene expression platform for biomarker discovery that approaches low density DNA arrays in numbers of genes analyzed while maintaining the high specificity, sensitivity and reproducibility that are characteristics of RT-PCR. Biomarkers discovered using this approach can be transferred to a clinical reference laboratory setting without having to re-validate the assay on a second technology platform.</p

Chemoenzymatic Probes for Detecting and Imaging Fucose-α(1-2)-galactose Glycan Biomarkers

The disaccharide motif fucose-α(1-2)-galactose (Fucα(1-2)Gal) is involved in many important physiological processes, such as learning and memory, inflammation, asthma, and tumorigenesis. However, the size and structural complexity of Fucα(1-2)Gal-containing glycans have posed a significant challenge to their detection. We report a new chemoenzymatic strategy for the rapid, sensitive detection of Fucα(1-2)Gal glycans. We demonstrate that the approach is highly selective for the Fucα(1-2)Gal motif, detects a variety of complex glycans and glycoproteins, and can be used to profile the relative abundance of the motif on live cells, discriminating malignant from normal cells. This approach represents a new potential strategy for biomarker detection and expands the technologies available for understanding the roles of this important class of carbohydrates in physiology and disease